|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
Phase 3 CLARIFY Trial Investigates 64Cu-SAR-bisPSMA PET for Improved Prostate Cancer Detection |
Louise Emmett, MD, MBChB, FRACP, FAANMS |
Louise Emmett discusses the novel copper-64 bisPSMA agent for prostate cancer imaging. She explains its unique features, including a 12-hour half-life and bifid peptide structure, which potentially offer improved imaging characteristics over existing PSMA agents. |
|
|
|
|
|
|
|
|
|
Comparing PSMA Ligands for Prostate Cancer Imaging |
Michael Hofman, MBBS, FRACP, FAANMS, FICIS, GAICD |
Alicia Morgans discusses advances in prostate cancer imaging and theranostics with Michael Hofman. Dr. Hofman emphasizes the growing variety of PSMA ligands for PET-CT imaging and treatment, comparing their subtle differences and implications for clinical practice. |
|
|
|
|
|
|
|
|
|
Examining Differences Between PSMA PET Imaging Agents "Presentation" |
Wolfgang Fendler, MD |
At the 2024 UCSF-UCLA PSMA Conference, Wolfgang Fendler discusses the relevance of different PSMA PET agents in clinical practice, emphasizing that while there are various ligands with kidney-dominant or liver-dominant excretion, their clinical impact appears minimal, suggesting PSMA-PET is a unified class of imaging with different logistical aspects. |
|
|
|
|
|
|
|
|
Do the Differences in PET Agents Matter? |
Wolfgang Fendler, MD |
Wolfgang Fendler discussed the relevance of different PSMA PET agents, such as 68Ga-PSMA-11 and 18F-PSMA-1007, in imaging for prostate cancer. He concluded that while specific agents may have unique advantages, like superior local detection with 18F-PSMA-1007, the choice of radioligand generally does not significantly impact clinical outcomes. Dr. Fendler emphasized the importance of understanding the physiological distribution and potential pitfalls of each agent to ensure accurate interpretation and recommended that clinical trials include a variety of radioligands. |
|
|
|
|
Alternative PSMA Ligands for Diagnostics and Treatment – Are They Interchangeable? |
Michael Hofman, MBBS, FRACP, FAANMS, FICIS, GAICD |
Michael Hofman discussed the interchangeability of alternative PSMA ligands for diagnostics and treatment. He emphasized that while 68Ga-PSMA-11 and 18F-DCFPyL are interchangeable with similar biodistribution, 18F-PSMA-1007 poses challenges due to benign bone uptake. He also noted that PSMA-617 and PSMA-I&T appear to be radio-equivalent for radioligand therapy. |
|
|
|
|
|
|
|
|
Combination Treatment of Prostate Cancer Using Pembrolizumab with PSMA Based Radioligands |
Thomas Hope, MD |
At the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, Dr. Thomas Hope presented on combining Pembrolizumab, an immune checkpoint inhibitor (ICI), with PSMA-based radioligand therapy for treating metastatic castration-resistant prostate cancer (mCRPC). Dr. Hope discussed how ICIs, like Pembrolizumab, block the PD-1/PD-L1 interaction, enabling T-cells to attack cancer cells. Given the typically low mutational burden in prostate cancer, responses to ICIs alone have been less effective. |
|
|
|
|
Comparison of 18F-Based PSMA Radiotracers with [68Ga]Ga-PSMA-11 in PET/CT Imaging of Prostate Cancer-a Systematic Review and Meta-Analysis - Beyond the Abstract
|
Siyu Huang |
This systematic review and meta-analysis compared [^18F]-based PSMA radiotracers ([^18F]DCFPyL, [^18F]PSMA-1007, and others) with [^68Ga]Ga-PSMA-11 in PET/CT imaging for prostate cancer. [^18F]DCFPyL demonstrated similar lesion detection and SUVmax to [^68Ga]Ga-PSMA-11, making it a suitable alternative. However, [^18F]PSMA-1007 showed a greater lesion SUVmax and a higher benign bone uptake, which could lead to false positives, making it less preferable despite its higher locoregional lesion detection. |
|
|
|
|
|
|
|
|